Munich, Germany, December 14, 2022 – CatalYm today announced three major expansions of its ongoing Phase 2 visugromab clinical development program. Based on initial positive patient responses, the company is advancing two potential lead indication cohorts into the second stage of the Simon-2-stage design ahead of schedule.

Munich, Germany, November 22, 2022 – CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion.

Schlieren / Zurich, Switzerland, and Osaka, Japan, November 1^st, 2022 – Memo Therapeutics AG ("MTx"), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd ("Ono").

Los Angeles, Calif., 26^th of October, 2022 – DEARhealth Inc., a health tech company focused on patients with a chronic condition and their continuous care management, announced today the launch of a randomized, multi-center, controlled study to assess the efficacy of DEARhealth's risk-based care management platform in improving the health of women with ovarian cancer.

Munich, Germany, September 26, 2022 – CatalYm today announced that it has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA) to expand its ongoing Phase 2 clinical program to include clinical trial centers in the U.S.

Schlieren/Zurich, Switzerland, May 31, 2022 – Memo Therapeutics AG ("MTx"), an innovator in the field of antibody discovery and development, announced today the initiation of a phase 1 clinical study targeting BK polyomavirus ("BKV") infection in renal transplant patients.

Gosselies/Belgium, 29 March 2022 – We are thrilled to announce today a new partnership with Synlab, Europe's leading clinical laboratory and medical diagnostic services provider.

Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing novel combination drugs for age-related diseases, today provides an update on its development pipeline and strategy.

Amsterdam, The Netherlands, 10^th March 2022 – Scenic Biotech BV ("Scenic"), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, is pleased to announce it has closed a Series A financing of ~$31 million (€28 million).

Munich, Germany, March 1^st, 2022 – CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company's lead product candidate, the GDF-15 neutralizing antibody CTL-002 (visugromab), at the confirmed target dose in five cohorts in combination with nivolumab in patients that are relapsed/refractory to anti-PD1/-L1 treatment and in one cohort that is anti-PD-1/-L1 naïve.